QuidelOrthoQDEL
QDEL
About: QuidelOrtho Corp is engaged in the development, manufacturing and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry and transfusion medicine which helps clinicians and patients to make decisions across the globe. Geographically the company has its presence in North America, EMEA, China and Other countries. It generates majority if its revenue from North America.
Employees: 6,600
0
Funds holding %
of 7,245 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
20% more repeat investments, than reductions
Existing positions increased: 104 | Existing positions reduced: 87
19% more call options, than puts
Call options by funds: $13.7M | Put options by funds: $11.6M
1.69% more ownership
Funds ownership: 108.95% [Q4 2024] → 110.64% (+1.69%) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 6 [Q4 2024] → 6 (+0) [Q1 2025]
4% less funds holding
Funds holding: 272 [Q4 2024] → 260 (-12) [Q1 2025]
18% less first-time investments, than exits
New positions opened: 32 | Existing positions closed: 39
20% less capital invested
Capital invested by funds: $3.26B [Q4 2024] → $2.61B (-$658M) [Q1 2025]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$25
15%
downside
Avg. target
$33
11%
upside
High target
$44
50%
upside
3 analyst ratings
1 positive
33%
1 neutral
33%
1 negative
33%
UBS Lu Li | 1%downside $29 | Neutral Maintained | 8 May 2025 |
Jefferies Tycho Peterson | 50%upside $44 | Buy Upgraded | 8 May 2025 |
JP Morgan Casey Woodring | 15%downside $25 | Underweight Maintained | 21 Apr 2025 |
Financial journalist opinion
Based on 12 articles about QDEL published over the past 30 days
Neutral
Zacks Investment Research
1 day ago
Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now
QDEL continues to witness growth on the back of its strong product portfolio.
Positive
Zacks Investment Research
1 week ago
Why QuidelOrtho (QDEL) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Neutral
Seeking Alpha
1 week ago
QuidelOrtho: Stagnant Growth Means Best To Avoid (Rating Downgrade)
Despite a once promising future, QuidelOrtho Corporation's current prospects are unappealing. I rated QuidelOrtho as a "Buy" in July 2023, but the stock has since declined by ~60% as its growth has stagnated. On 05/07/2025 the company reported top and bottom-line beats for its Q1/2025 earnings, bumping its shares up >40%.
Positive
Zacks Investment Research
1 week ago
QuidelOrtho Stock Gains Following Q1 Earnings Beat, Margins Expand
Despite solid performances by the Labs and Immunohematology units and EMEA and Other regions, QDEL reports soft overall top-line results in first-quarter 2025.
Neutral
Seeking Alpha
2 weeks ago
QuidelOrtho Corporation (QDEL) Q1 2025 Earnings Call Transcript
QuidelOrtho Corporation (NASDAQ:QDEL ) Q1 2025 Results Conference Call May 7, 2025 5:00 PM ET Company Participants Juliet Cunningham - Vice President, Investor Relations Brian Blaser - President and Chief Executive Officer Joe Busky - Chief Financial Officer Conference Call Participants Conor McNamara - RBC Capital Patrick Donnelly - Citi Andrew Brackmann - William Blair Jack Meehan - Nephron Research Lu Li - UBS Casey Woodring - JPMorgan Andrew Cooper - Raymond James Tycho Peterson - Jefferies Operator Welcome to the QuidelOrtho First Quarter 2025 Financial Results Conference Call and Webcast. At this time, all participant lines are in listen mode only.
Positive
Zacks Investment Research
2 weeks ago
QuidelOrtho (QDEL) Q1 Earnings and Revenues Top Estimates
QuidelOrtho (QDEL) came out with quarterly earnings of $0.74 per share, beating the Zacks Consensus Estimate of $0.58 per share. This compares to earnings of $0.44 per share a year ago.
Neutral
Business Wire
2 weeks ago
QuidelOrtho Reports First Quarter 2025 Financial Results
SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs, and transfusion medicine, today announced financial results for the first quarter ended March 30, 2025. “We delivered solid first quarter performance driven by growth in our Labs business and the strength of our recurring revenue business model,” said Brian J. Blaser, President an.
Neutral
Zacks Investment Research
2 weeks ago
MedTech Stocks' Earnings to Watch on May 7: COR, QDEL & INGN
The medical device sector saw steady sales growth in the first quarter of 2025, supported by innovation in AI, wearables, and personalized care. However, earnings gains were more modest as global tariffs, inflationary costs, and supply chain disruptions continued to pressure margins.
Positive
Zacks Investment Research
3 weeks ago
4 MedTech Stocks Poised to Outshine Q1 Earnings Estimates
MedTech companies' quarterly results are likely to reflect base business recovery on a year-over-year basis. Let's see how HIMS, GMED, QDRL and HAE are poised ahead of their earnings release.
Positive
Zacks Investment Research
3 weeks ago
QuidelOrtho (QDEL) Earnings Expected to Grow: Should You Buy?
QuidelOrtho (QDEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Charts implemented using Lightweight Charts™